GlassScriptPhysician profile
Hongkai Cui
NPI 1649031782
$1,718.77
in general payments reported to CMS, 2019-2025
16 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $418 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $383.02 | 2024-2025 | Evenity, Otezla, Repatha |
| Gilead Sciences, INC. | $275.89 | 2024-2025 | Vemlidy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.35 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $182.80 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $168.64 | 2025 | Wegovy, Ozempic |
| Corcept Therapeutics | $143.21 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $89.37 | 2024-2025 | |
| Glaxosmithkline, LLC. | $75.46 | 2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $47.31 | 2024-2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $37.96 | 2025 | Wavewriter Alpha Prime 16 |
| Optinose US, INC. | $22.78 | 2025 | |
| Merck Sharp & Dohme LLC | $18.92 | 2024 | Gardasil, Capvaxive, Vaqta |
| Esperion Therapeutics, INC. | $18.38 | 2025 | Nexletol |
| Hologic Sales and Service, LLC | $17.17 | 2025 | Aptima, Thinprep 2000 Processor |
| Abbvie INC. | $16.48 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $15.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hongkai Cui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.